Missed GME or NVDA? Don’t Miss the Next One.​
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
LIVN Stock Forecast 2025-2026
$43.18
Current Price
$2.35B
Market Cap
Buy 9
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to LIVN Price Targets
+83.0%
To High Target of $79.00
+39.0%
To Median Target of $60.00
+22.7%
To Low Target of $53.00
LIVN Price Momentum
-2.7%
1 Week Change
+18.9%
1 Month Change
-27.3%
1 Year Change
-6.8%
Year-to-Date Change
-30.3%
From 52W High of $61.94
+32.9%
From 52W Low of $32.48
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching LivaNova (LIVN) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on LIVN and similar high-potential opportunities.
Latest LIVN Stock Price Targets & Analyst Predictions
Based on our analysis of 13 Wall Street analysts, LIVN has a bullish consensus with a median price target of $60.00 (ranging from $53.00 to $79.00). The overall analyst rating is Strong Buy (8.5/10). Currently trading at $43.18, the median forecast implies a 39.0% upside. This outlook is supported by 9 Buy, 2 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
LIVN Analyst Ratings
9
Buy
2
Hold
0
Sell
LIVN Price Target Range
Low
$53.00
Average
$60.00
High
$79.00
Current: $43.18
Latest LIVN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for LIVN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 20, 2025 | Wolfe Research | Mike Polark | Outperform | Upgrade | $60.00 |
| May 13, 2025 | Needham | Mike Matson | Buy | Reiterates | $64.00 |
| May 8, 2025 | Barclays | Matt Miksic | Equal-Weight | Maintains | $55.00 |
| May 8, 2025 | Baird | David Rescott | Outperform | Maintains | $61.00 |
| Mar 17, 2025 | Needham | Mike Matson | Buy | Reiterates | $64.00 |
| Mar 7, 2025 | Barclays | Matt Miksic | Equal-Weight | Maintains | $56.00 |
| Mar 3, 2025 | Goldman Sachs | David Roman | Buy | Maintains | $55.00 |
| Feb 26, 2025 | Needham | Mike Matson | Buy | Maintains | $64.00 |
| Feb 26, 2025 | Stifel | Rick Wise | Buy | Maintains | $60.00 |
| Feb 26, 2025 | Mizuho | Anthony Petrone | Outperform | Maintains | $60.00 |
| Jan 28, 2025 | Needham | Mike Matson | Buy | Reiterates | $75.00 |
| Nov 25, 2024 | Needham | Mike Matson | Buy | Reiterates | $75.00 |
| Nov 12, 2024 | Needham | Mike Matson | Buy | Reiterates | $75.00 |
| Oct 31, 2024 | Baird | David Rescott | Outperform | Maintains | $72.00 |
| Oct 31, 2024 | Mizuho | Anthony Petrone | Outperform | Maintains | $70.00 |
| Oct 31, 2024 | Needham | Mike Matson | Buy | Reiterates | $75.00 |
| Oct 4, 2024 | Goldman Sachs | David Roman | Buy | Initiates | $65.00 |
| Sep 17, 2024 | Baird | David Rescott | Outperform | Upgrade | $66.00 |
| Aug 28, 2024 | Baird | Mike Polark | Neutral | Maintains | $55.00 |
| Aug 1, 2024 | Baird | Mike Polark | Neutral | Maintains | $55.00 |
LivaNova PLC (LIVN) Competitors
The following stocks are similar to LivaNova based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
LivaNova PLC (LIVN) Financial Data
LivaNova PLC has a market capitalization of $2.35B with a P/E ratio of 30.3x. The company generates $1.28B in trailing twelve-month revenue with a -17.4% profit margin.
Revenue growth is +7.4% quarter-over-quarter, while maintaining an operating margin of +15.5% and return on equity of -19.7%.
Valuation Metrics
Market Cap
$2.35B
Enterprise Value
$2.32B
P/E Ratio
30.3x
PEG Ratio
11.6x
Price/Sales
1.8x
Growth & Margins
Revenue Growth (YoY)
+7.4%
Gross Margin
+69.7%
Operating Margin
+15.5%
Net Margin
-17.4%
EPS Growth
+7.4%
Financial Health
Cash/Price Ratio
+31.4%
Current Ratio
1.6x
Debt/Equity
65.5x
ROE
-19.7%
ROA
+4.6%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
LivaNova PLC (LIVN) Business Model
About LivaNova PLC
What They Do
Develops innovative medical devices for healthcare.
Business Model
LivaNova generates revenue by designing, manufacturing, and selling advanced medical devices primarily for cardiac surgery and neuromodulation. The company partners with hospitals, clinics, and healthcare professionals to deliver its products, which are essential for improving patient outcomes in complex medical procedures.
Additional Information
Headquartered in London, LivaNova is known for its expertise in cardiopulmonary and heart valve systems, as well as neurologic therapeutic devices aimed at treating conditions such as epilepsy and depression. The company plays a critical role in the medical device industry, significantly enhancing the quality of life for patients globally.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
2,900
CEO
Mr. Vladimir A. Makatsaria
Country
United Kingdom
IPO Year
2015
Website
www.livanova.comLivaNova PLC (LIVN) Latest News & Analysis
Latest News
Quick Summary
LivaNova PLC CEO Vladimir Makatsaria will speak at the Jefferies Global Healthcare Conference on June 5 at 3:10 p.m. ET. The event will be webcast for registered attendees.
Why It Matters
LivaNova's CEO speaking at the Jefferies Global Healthcare Conference can signal strategic insights, potential partnerships, or product developments, influencing investor sentiment and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
LivaNova PLC will hold its Q1 2025 earnings call on May 7, 2025, at 8:00 AM ET, featuring key executives and analysts from major financial firms.
Why It Matters
LivaNova's Q1 2025 earnings call provides insights into its financial health and strategic direction, influencing stock performance and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
LivaNova PLC reported Q1 2025 revenue of $316.9 million, up 7.4% year-over-year. It posted a diluted loss per share of $6.01, influenced by SNIA. Full-year guidance updated.
Why It Matters
LivaNova's revenue growth signals strong market performance, but the significant loss per share raises concerns about profitability, influencing investors' sentiment and stock valuation.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
LivaNova (LIVN) reported Q3 earnings of $0.88 per share, exceeding estimates of $0.75, and up from $0.73 per share year-over-year.
Why It Matters
LivaNova's earnings beat estimates and show year-over-year growth, indicating strong performance and potential for stock price appreciation, positively impacting investor sentiment.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
LivaNova PLC (Nasdaq: LIVN) reported 12-month data from its OSPREY trial, showing a 65% responder rate for its aura6000â„¢ System in treating moderate to severe obstructive sleep apnea.
Why It Matters
Positive trial results for LivaNova's aura6000â„¢ System indicate strong efficacy in treating sleep apnea, potentially boosting market demand and investor confidence in the company's growth prospects.
Source: Business Wire
Market Sentiment:
Neutral
LivaNova to Announce First-Quarter 2025 Results
1 month ago
Quick Summary
LivaNova PLC will hold a conference call on May 7, 2025, at 1 p.m. London time to discuss its Q1 2025 financial results.
Why It Matters
LivaNova PLC's upcoming conference call indicates upcoming financial performance insights, impacting stock evaluations and investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About LIVN Stock
What is LivaNova PLC's (LIVN) stock forecast for 2025?
Based on our analysis of 13 Wall Street analysts, LivaNova PLC (LIVN) has a median price target of $60.00. The highest price target is $79.00 and the lowest is $53.00.
Is LIVN stock a good investment in 2025?
According to current analyst ratings, LIVN has 9 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $43.18. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for LIVN stock?
Wall Street analysts predict LIVN stock could reach $60.00 in the next 12 months. This represents a 39.0% increase from the current price of $43.18. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is LivaNova PLC's business model?
LivaNova generates revenue by designing, manufacturing, and selling advanced medical devices primarily for cardiac surgery and neuromodulation. The company partners with hospitals, clinics, and healthcare professionals to deliver its products, which are essential for improving patient outcomes in complex medical procedures.
What is the highest forecasted price for LIVN LivaNova PLC?
The highest price target for LIVN is $79.00 from at , which represents a 83.0% increase from the current price of $43.18.
What is the lowest forecasted price for LIVN LivaNova PLC?
The lowest price target for LIVN is $53.00 from at , which represents a 22.7% increase from the current price of $43.18.
What is the overall LIVN consensus from analysts for LivaNova PLC?
The overall analyst consensus for LIVN is bullish. Out of 13 Wall Street analysts, 9 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $60.00.
How accurate are LIVN stock price projections?
Stock price projections, including those for LivaNova PLC, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 23, 2025 6:20 PM UTC